Bifeprunox in the Treatment of Schizophrenia

Status:
Completed

Trial end date:
2006-11-01

Target enrollment:

Participant gender:

Study of the long-term efficacy and safety of bifeprunox in the treatment of schizophrenia.

Phase 3

Solvay Pharmaceuticals